Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoffrey Dusheiko

Showing results (71-80 of 115) with videos related to

Pageof 12
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 21, 2020
Circulating Pregenomic Hepatitis B Virus RNA Is Primarily Full-length in Chronic Hepatitis B Patients Undergoing Nucleos(t)ide Analogue TherapyMark Anderson, Jeffery Gersch, Ka-Cheung Luk, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|February 14, 2004
Occult hepatitis B virus infection does not affect liver histology or response to therapy with interferon alpha and ribavirin in intravenous drug users with chronic hepatitis CPaolo Fabris, Dave Brown, Giulia Tositti, et al.
Journal of Virology|May 14, 2004
Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapyGeorge J M Webster, Stephanie Reignat, David Brown, et al.
Journal of Hepatology|February 11, 2014
Patient-important benefits of clearing the hepatitis C virus through treatment: a simulation modelHamish Innes, David Goldberg, Geoffrey Dusheiko, et al.
Gastroenterology|February 5, 2008
Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approachJean-Michel Pawlotsky, Geoffrey Dusheiko, Angelos Hatzakis, et al.
Clinical Endocrinology|February 13, 2010
Thyroid dysfunction in a UK hepatitis C population treated with interferon-alpha and ribavirin combination therapySeán J Costelloe, Nancy Wassef, Josephine Schulz, et al.
Journal of Hepatology|April 10, 2014
Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: the VALENCE studyZobair M Younossi, Maria Stepanova, Stefan Zeuzem, et al.
Hepatology (Baltimore, Md.)|February 24, 2006
The influence of T cell cross-reactivity on HCV-peptide specific human T cell responsePatrick T F Kennedy, Simonetta Urbani, Rebecca A Moses, et al.
The American Journal of Gastroenterology|October 3, 2022
Results of a Model of Delivering Hepatitis C Care in a Homeless Metropolitan Population in EnglandMaría Fernanda Guerra-Veloz, Khin Han, Kathryn Oakes, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 30, 2015
Liver Fibrosis by Transient Elastography and Virologic Outcomes After Introduction of Tenofovir in Lamivudine-Experienced Adults With HIV and Hepatitis B Virus Coinfection in GhanaAlexander J Stockdale, Richard Odame Phillips, Apostolos Beloukas, et al.
Pageof 12

Showing results (71-80 of 115) with videos related to

Sort By:
Pageof 12
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 21, 2020
Circulating Pregenomic Hepatitis B Virus RNA Is Primarily Full-length in Chronic Hepatitis B Patients Undergoing Nucleos(t)ide Analogue TherapyMark Anderson, Jeffery Gersch, Ka-Cheung Luk, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|February 14, 2004
Occult hepatitis B virus infection does not affect liver histology or response to therapy with interferon alpha and ribavirin in intravenous drug users with chronic hepatitis CPaolo Fabris, Dave Brown, Giulia Tositti, et al.
Journal of Virology|May 14, 2004
Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapyGeorge J M Webster, Stephanie Reignat, David Brown, et al.
Journal of Hepatology|February 11, 2014
Patient-important benefits of clearing the hepatitis C virus through treatment: a simulation modelHamish Innes, David Goldberg, Geoffrey Dusheiko, et al.
Gastroenterology|February 5, 2008
Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approachJean-Michel Pawlotsky, Geoffrey Dusheiko, Angelos Hatzakis, et al.
Clinical Endocrinology|February 13, 2010
Thyroid dysfunction in a UK hepatitis C population treated with interferon-alpha and ribavirin combination therapySeán J Costelloe, Nancy Wassef, Josephine Schulz, et al.
Journal of Hepatology|April 10, 2014
Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: the VALENCE studyZobair M Younossi, Maria Stepanova, Stefan Zeuzem, et al.
Hepatology (Baltimore, Md.)|February 24, 2006
The influence of T cell cross-reactivity on HCV-peptide specific human T cell responsePatrick T F Kennedy, Simonetta Urbani, Rebecca A Moses, et al.
The American Journal of Gastroenterology|October 3, 2022
Results of a Model of Delivering Hepatitis C Care in a Homeless Metropolitan Population in EnglandMaría Fernanda Guerra-Veloz, Khin Han, Kathryn Oakes, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 30, 2015
Liver Fibrosis by Transient Elastography and Virologic Outcomes After Introduction of Tenofovir in Lamivudine-Experienced Adults With HIV and Hepatitis B Virus Coinfection in GhanaAlexander J Stockdale, Richard Odame Phillips, Apostolos Beloukas, et al.
Pageof 12